The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2331-2336

  Siissalo, Sanna ^a   Zhang, Hongbo ^a   Stilgenbauer, Eric ^a   Kaukonen, Ann Marie ^a   Hirvonen, Jouni ^a   Finel, Moshe ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHOL; BETA ACTIN; ESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A6; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN CACO 2; COLON CANCER; DRUG ABSORPTION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; GLUCURONIDATION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CACO-2 CELLS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; HUMANS; NAPHTHOLS; SUBSTRATE SPECIFICITY;

EID: 54349123557     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022335     Document Type: Article

References (40)

1. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, and Languth P (1998) P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression level. J Pharm Sci 87:757-762.
2. Briske-Anderson M, Finley J, and Newman S (1997) The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 214:248-257.
3. Chantret I, Barbat A, Dussaulx E, Brattain MG, and Zweibaum A (1988) Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 48:1936-1942.
4. Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM, and Gjellan K (2001) Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214.
5. Gan LS and Thakker DR (1997) Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23:77-98.
6. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354-363.
7. Guillemette C, Belanger A, and Lepine J (2004) Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6:246-254.
8. Hidalgo IJ, Raub TJ, and Borchardt RT (1989) Characterization of the human intestinal carcinoma cell line (Caco-2) as a model system for intestinal epithelial transport. Gastroenterology 96:736-749.
9. Hilgers AR, Conradi RA, and Burton PS (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7:902-910.
10. Hodin RA, Shei A, and Meng S (1997) Transcriptional activation of the human villin gene during enterocyte differentiation. J Gastrointest Surg 1:433-438.
11. Ishida K, Honda M, Shimizu T, Taguchi M, and Hashimoto Y (2007) Stereoselective metabolism of carvedilol by the β-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. Biol Pharm Bull 30:1930-1933.
12. Itäaho K, Mackenzie P, Ikushiro SI, Miners J, and Fenel M (2008) The configuration of the 17-hydroxy group variably influences the glucuronidation of β-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos 36:2307-2315.
13. Jeong EJ, Liu X, Jia X, Chen J, and Hu M (2005a) Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab 6:455-468.
14. Jeong EJ, Liu Y, Lin H, and Hu M (2005b) Species and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794.
15. Köhle C, Badary OA, Nill K, Bock-Hennig BS, and Bock KW (2005) Serotonin glucuronidation by Ah receptor- and oxidative stress-inducible human UDP-glucuronosyltransferase (UGT) 1A6 in Caco-2 cells. Biochem Pharmacol 69:1397-1402.
16. Koljonen M, Hakala KS, Ahtola-Sätilä T, Laitinen L, Kostiainen R, Kotiaho T, Kaukonen AM, and Hirvonen J (2006) Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Eur J Pharm Biopharm 64:379-387.
17. Kurkela M, Garcia-Horsman JA, Luukkanen L, Morsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, and Finel M (2003) Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem 278:3536-3544.
18. Lépine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, Belanger A, and Guillemette C (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
19. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
20. Meinl W, Ebert B, Glatt H, and Lampen A (2008) Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism. Drug Metab Dispos 36:276-283.
21. Meunier V, Bourrié M, Berger Y, and Fabre G (1995) The human intestinal epithelial cell line Caco-2: pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194.
22. Miret S, Abrahamse L, and De Groene EM (2004) Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J Biomed Screen 9:598-606.
23. Mizuma T, Momota R, Haga M, and Hayashi M (2004) Factors affecting glucuronidation activity in Caco-2 cells. Drug Metab Pharmacokinet 19:130-134.
24. Muller PY, Janovjak H, Miserez AR, and Dobbie Z (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372-1378.
25. Münzel PA, Schmohl S, Heel H, Kälberer K, Bock-Hennig BS, and Bock KW (1999) Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos 27:569-573.
26. Naganuma M, Saruwatari A, Okamura S, and Tamura H (2006) Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells. Biol Pharm Bull 29:1476-1479.
27. Peters WHM and Roelofs HMJ (1989) Time-dependent activity and expression of glutathione S-transferases in the human colon adenocarcinoma cell line Caco-2. Biochem J 264:613-616.
28. Pfeiffer E, Treiling CR, Hoehle SI, and Metzler M (2005) Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis 26:2172-2178.
29. Radominska-Pandya A, Czernik P, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-900.
30. Sabolovic N, Humbert AC, Radominska-Pandya A, and Magdalou J (2006) Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27:181-189.
31. Sabolovic N, Magdalou J, Netter P, and Abid A (2000) Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life Sci 67:185-196.
32. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, and Watkins PB (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 51:741-754.
33. Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, and Kaukonen AM (2007) Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine induced Caco-2 cell lines. Eur J Pharm Biopharm 67:548-554.
34. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
35. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
36. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
37. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
38. Vachon PH and Beaulieu JF (1992) Transient mosaic patterns of morphological and functional differentiation in the Caco-2 cell line. Gastroenterology 103:414-423.
39. Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, and Wood AJJ (1999) P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
40. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, et al. (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281-290.